

21

SUB
E

1. (Twice Amended) A discrete solid pharmaceutical composition comprising particulate valdecoxib in an amount of about 5 mg to about 40 mg per dose and one or more pharmaceutically acceptable excipients, wherein a single oral administration of the composition, in an amount containing about 20 mg of valdecoxib, to a fasting subject provides a time course of blood serum concentration of valdecoxib having a time to reach a concentration of 20 ng/ml not greater than about 0.5 h after administration.

IN THE SPECIFICATION

Please delete the sentence beginning on line 27 of Page 3 which provides a brief description of Figure 3.

Please delete the sentence beginning on line 29 of Page 3 and replace it with the following re-written sentence: -- Figure 3 is a graph showing plasma concentration of valdecoxib in humans following oral administration of valdecoxib tablets of the invention. --

Please delete Example 4 spanning lines 7 - 14 on page 24.

Please delete the header beginning on line 15 of Page 24 and replace it with the following re-written header: -- Example 4: Pharmacokinetic properties of valdecoxib in humans --

Please delete Fig. 3 and the accompanying figure legend on Sheet 3.

Please change the Fig. 4 legend on Sheet 3 of 3 to the following re-written legend: -- Fig.

3 --

REMARKS

By the present amendment, eight (8) dependent claims are cancelled and one (1) claim is amended. No fees for additional claims are believed payable.

Claims 11 - 17 and 18 are cancelled in order to expedite prosecution by focusing the present application on a preferred embodiment of the invention. Applicant reserves the right to reintroduce one or more of these cancelled claims in continuing applications.

Claim 1 is amended herein to focus prosecution on a presently preferred embodiment of the invention in which the pharmaceutical composition is in discrete solid form. Support for this amendment can be found in the application as originally filed at least at page 3, line 9.